Accelerating Acromegaly Care: Patient Perspectives, Clinical Advances, and Personalized Management Approaches

Accelerating Acromegaly Care: Patient Perspectives, Clinical Advances, and Personalized Management Approaches
Partner Image

Activity Snapshot

Activity Type:
Online Activity
Release Date:
August 15, 2023
Expiration Date:
August 14, 2024
Activity Price:
Free
Continuing Education Credits:
Estimated Duration:
1 hour
Content Last Reviewed:
August 15, 2023

Faculty

Maria Fleseriu, MD, FACE

Speaker
Maria Fleseriu, MD, FACE

Professor of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition and Professor of Neurological Surgery, Oregon Health and Science University Director OHSU Pituitary Center
Portland, Oregon

Susan L. Samson, MD, PhD, FRCPC, FACE

Speaker
Susan L. Samson, MD, PhD, FRCPC, FACE

Chair, Division of Endocrinology, Diabetes and Metabolism
Mayo Clinic
Jacksonville, Florida

Jill Sisco

Speaker
Jill Sisco

Patient Advocate

Jonathan Kahan

Speaker
Jonathan Kahan

Patient Advocate

Richa Bhattarai, MD

Planner

Endocrinologist
California

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Planner

Adult Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, IN

Michele B Kaufman, PharmD, BCGP

Peer Reviewer

Pharmacist
New York Presbyterian Hospital - Lower Manhattan
New York, NY

Agenda

  1. Pathophysiology, Clinical Manifestations, and Burden of Acromegaly
  2. Real-World Insights from Acromegaly Patients
  3. Evidence-Based Diagnosis of Acromegaly
  4. Current and Emerging Acromegaly Treatment Approaches: The Latest Data
  5. Differentiating and Individualizing Treatment Approach Based on Clinical Evidence and Patient Characteristics
  6. Leading Strategies for Patient Engagement and Shared Decision-Making

Learning Objectives

  • Assess the underlying pathophysiology of acromegaly and connection to clinical manifestations to support early recognition of signs/symptoms and timely, guideline-recommended diagnosis
  • Describe the clinical and psychosocial burden and unmet needs of patients with acromegaly
  • Differentiate current and emerging acromegaly treatments based on their indication, route, frequency of administration, and the latest clinical evidence for their safety and efficacy
  • Integrate effective strategies for patient engagement and shared decision-making to develop personalized treatment plans that optimize patient outcomes, adherence, and quality of life

Activity Overview

Intended Audience: Endocrinologists, primary care physicians, and their clinical teams of NPs, PAs, nurses, and pharmacists

Take part in this engaging video activity as two patients with acromegaly share their personal stories and provide insight on the everyday challenges, care experiences, and impact on quality of life associated with living with this rare and burdensome disorder.

Responding to the patient testimonials, two acromegaly experts will provide an overview of acromegaly's pathophysiology, diverse clinical manifestations, and best diagnostic practices, as well as engage in in-depth discussions on the latest guidelines and clinical evidence for current and emerging acromegaly treatments, approaches to personalize treatment to the needs and goals of individual acromegaly patients, and leading strategies for effective care coordination and patient engagement.

This activity is delivered in partnership with the Acromegaly Community.

Accreditation Information

Joint Accreditation Statement

IPCE Credit™In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement

ACCME Logo

PRIME® designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA Logo

PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

Nurse Practitioner LogoPRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.3 hour of pharmacology).

Pharmacist Accreditation Statement

ACPE Logo

This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-23-190-H01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy).

Nurse Accreditation Statement

ANCC Logo

PRIME® designates this activity for 1.0 contact hour.

Obtaining CE Credit

  1. Complete the pre-activity evaluation
  2. Complete the activity in its entirety
  3. Complete a post-activity evaluation
  4. Download and/or print a certificate of completion and/or submit CE credits electronically

Device Requirements

  • Computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

  • Maria Fleseriu, MD, FACE (Speaker)
    Advisory Board or PanelCamurus, Ipsen
    ConsultantAmryt, Ipsen, Pfizer, Recordati
    Grants / Research SupportAmryt, Crinetics, Ionis, Ipsen, Recordati
    The relationships reported above are related to the following therapeutic area: Endocrinology and Metabolism
  • Jill Sisco (Speaker)
    Speakers Bureau or other Promotional EducationAmryt, Novo Nordisk, Pfizer, Recordati
    The relationships reported above are related to the following therapeutic area: Endocrinology and Metabolism
  • Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
    Speakers Bureau or other Promotional EducationAstraZeneca, Bristol-Myers Squibb, CTI, DSI, Eli Lilly and Company, Gilead Sciences, Morphosys, Pfizer
    The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

  • Susan L. Samson, MD, PhD, FRCPC, FACE (Speaker)
  • Jonathan Kahan (Speaker)
  • Michele B Kaufman, PharmD, BCGP (Reviewer)
  • Richa Bhattarai, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.

Recommended Activities

Funding Disclosure

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by educational grants from Amryt Pharmaceuticals DAC, and Ipsen Biopharmaceuticals, Inc.

Accessibility Statement

At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.